Extracellular signal-regulated kinase 5 (ERK5) is a member of the mitogen-activated protein kinase family whose biological function in the CNS has not been defined. In contrast to ERK1 and ERK2, which are activated by neurotrophins (NTs), cAMP, and neuronal activity in cortical neurons, ERK5 is activated only by NTs. Here, we report that ERK5 expression is high in the brain during early embryonic development but declines as the brain matures to almost undetectable levels by postnatal day (P) 49. Interestingly, expression of a dominant-negative ERK5 blocked brain-derived neurotrophic factor protection against trophic withdrawal in primary cortical neurons cultured from embryonic day (E) 17 but not P0. Furthermore, expression of a dominant-negative ERK5 induced apoptosis in E17 but not P0 cortical neurons maintained in the presence of serum. We also present evidence that ERK5 protection of E17 cortical neurons may be mediated through myocyte enhancer factor 2-induced gene expression. These data suggest that ERK5 activation of myocyte enhancer factor 2-induced gene expression may play an important and novel role in the development of the CNS by mediating NT-promoted survival of embryonic neurons.N eurotrophins (NTs) have profound effects on the development of the CNS and regulate differentiation, survival, and adaptive responses of neurons. For example, NTs protect many types of neurons from apoptosis both during development and in the adult (1-6). Consequently, there is an intense interest in elucidating mechanisms for NT-mediated neuroprotection and its contribution to the development of the CNS. NTs including nerve growth factor, brain-derived neurotrophic factor (BDNF), NT3, NT4͞5, and NT6 bind to and activate specific receptor tyrosine kinases of the Trk family (7,8). Upon binding to and activating Trk, NTs can activate several intracellular signaling transduction systems including the phosphatidylinositol 3-kinase, protein kinase C, and extracellular signal-regulated kinase 1͞2 (ERK1͞2) pathways (8-11).Recently, a new member of the mitogen-activated protein (MAP) kinase family, ERK5 (also known as the big MAP kinase 1 or BMK1) was discovered (12, 13). ERK5 is widely expressed in many tissues including brain. Although ERK5 contains a similar TEY dual-phosphorylation motif as ERK1͞2 and the N-terminal half of ERK5 shares sequence homology with other members of the MAP kinase family, a large C terminus and a unique loop-12 sequence distinguish it from ERK1͞2 and other MAP kinase family members. ERK5 is phosphorylated and activated by MAP kinase kinase (MEK) 5, but not by MEK1 or MEK2 (12,14). MEK5 is specific for ERK5 and does not phosphorylate ERK1͞2, c-Jun N-terminal protein kinase, or p38 MAP kinase (12,14). A number of substrates have been identified for activated ERK5 including myocyte enhancer factor 2C (MEF2C) (15-17). Like ERK1͞2, ERK5 is activated by serum, epidermal growth factor, nerve growth factor, and G protein-coupled receptors (15)(16)(17)(18)(19). In contrast to ERK1 and ERK2, which are activat...